The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of CASP7 protein; [gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of PARP1 protein; Acetylcysteine affects the reaction [[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of CASP7 protein]; Acetylcysteine affects the reaction [[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of PARP1 protein]; gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]
gambogic acid affects the expression of BCL2 protein [Verapamil co-treated with gambogic acid] results in decreased expression of BCL2 protein; Fluorouracil promotes the reaction [gambogic acid results in decreased expression of BCL2 mRNA]
[gambogic acid co-treated with Doxorubicin] affects the expression of BIRC5 protein; SB 203580 affects the reaction [[gambogic acid co-treated with Doxorubicin] affects the expression of BIRC5 protein] gambogic acid affects the expression of BIRC5 protein
[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [Verapamil co-treated with gambogic acid] results in increased cleavage of and results in increased activity of CASP3 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Fluorouracil promotes the reaction [gambogic acid results in decreased expression of CASP3 mRNA]
[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of CASP7 protein; Acetylcysteine affects the reaction [[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of CASP7 protein]
[gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [Verapamil co-treated with gambogic acid] results in increased cleavage of and results in increased activity of CASP8 protein
gambogic acid results in decreased expression of CASP9 protein alternative form [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [Verapamil co-treated with gambogic acid] results in increased cleavage of and results in increased activity of CASP9 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]
[Verapamil co-treated with gambogic acid] results in increased expression of DDIT3 protein; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]
Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]
gambogic acid results in increased cleavage of PARP1 protein gambogic acid results in decreased expression of PARP1 mRNA [gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of PARP1 protein; [Verapamil co-treated with gambogic acid] results in increased cleavage of PARP1 protein; Acetylcysteine affects the reaction [[gambogic acid affects the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]] which affects the cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [[Verapamil co-treated with gambogic acid] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[Verapamil co-treated with gambogic acid] results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; Fluorouracil promotes the reaction [gambogic acid results in decreased expression of PARP1 mRNA]; Fluorouracil promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]
gambogic acid results in decreased expression of TYMS mRNA gambogic acid inhibits the reaction [Fluorouracil results in increased expression of TYMS mRNA]